May 16, 2008 —
Phenomix Corporation announced that PHX1149, a dipeptidyl peptidase-4 (DPP-4) inhibitor, demonstrated positive results in a Phase 2b clinical trial for the treatment of Type 2 diabetes.
The 12-week, double-blind, placebo-controlled clinical trial involving 422 randomized patients compared PHX1149 in once-daily oral doses of 200 milligrams and 400 milligrams to placebo. Patients were allowed to continue selected anti-diabetic drugs, either metformin or a thiazolidinedione, or a combination of the two, at a constant dose during the trial. PHX1149 demonstrated statistically significant reductions in hemoglobin A1c (HbA1c) in both the 200 milligram and 400 milligram dose groups...
Phenomix's Press Release -
October 23, 2008 — Forest Laboratories, Inc. (NYSE: FRX) and Phenomix Corporation today announced that they have entered into a definitive collaboration agreement to develop and commercialize dutogliptin (PHX1149) in North America. 
Dutogliptin is Phenomix’ proprietary orally administered, small molecule dipeptidyl-peptidase-4 (DPP-4) inhibitor currently undergoing Phase 3 clinical development in Type 2 diabetes mellitus... Phenomix's Press Release - Forest Laboratories' Press Release -
